CytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Report

CytomX Therapeutics reported a Q1 2024 QQ1 quarter characterized by a strong revenue base driven by collaboration activity and meaningful clinical progress for CX-904, its EGFR-CD3 Probody T-cell engager. Revenue of $41.46 million delivered a gross profit of $41.46 million with an EBITDA of $12.12 million and a net income of $13.79 million, aided by approximately $2.18 million of other income and favorable non-operating items. Management highlighted the Phase I CX-904 dose-escalation program, noting an encouraging safety profile with no CRS or ICANS across non-step dosing and step-dose cohorts, and early signs of antitumor activity in pancreatic cancer (including confirmed partial responses) and disease control in a broader set of EGFR-positive tumors. The company also underscored steady progress across the pipeline (CX-2051, CX-801) and ongoing collaboration milestones (e.g., $10 million in milestone payments from the Astellas bispecific collaboration). Net cash flow from operations was negative (-$26.0 million) driven largely by working capital movements, while cash on hand showed a balance of $36.2 million at period-end under the reported balance sheet, with citations in the call noting a cash runway into 2025 subject to collaborations and future milestones. This juxtaposition of a robust revenue base from partnerships with early-stage clinical momentum in CX-904 establishes CytomX as a collaboration-centric biotech with optionality across multiple Probody programs. Investors should monitor the Company’s ability to extend MXD-like cash runway via milestones, the evolution of RP2D for CX-904, and data readouts for its EpCAM and interferon assets in 2025–2026.